CoChat

Designed endocytosis-inducing proteins degrade targets and amplify signals

Open access
Huang, Buwei, Abedi, Mohamad, Ahn, Green, Coventry, Brian, Sappington, Isaac, Tang, Cong, Wang, Rong, Schlichthaerle, Thomas, Zhang, Jason Z., Wang, Yujia, Goreshnik, Inna, Chiu, Ching Wen, Chazin-Gray, Adam, Chan, Sidney, Gerben, Stacey, Murray, Analisa, Wang, Shunzhi, O’Neill, Jason, Yi, Li, Yeh, Ronald, Misquith, Ayesha, Wolf, Anitra, Tomasovic, Luke M., Piraner, Dan I., Duran Gonzalez, Maria J., Bennett, Nathaniel R., Venkatesh, Preetham, Ahlrichs, Maggie, Dobbins, Craig, Yang, Wei, Wang, Xinru, Sahtoe, Danny D., Vafeados, Dionne, Mout, Rubul, Shivaei, Shirin, Cao, Longxing, Carter, Lauren, Stewart, Lance, Spangler, Jamie B., Roybal, Kole T., Greisen, Per Jr, Li, Xiaochun, Bernardes, Gonçalo J. L., Bertozzi, Carolyn R., Baker, David · 2025 · Nature
Cited by 146

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

(KineTACs) have used this to target specific proteins for degradation by fusing modified native ligands to target binding proteins. Although powerful, these approaches can be limited by competition with native ligands and requirements for chemical modification that limit genetic encodability and can complicate manufacturing, and, more generally, there may be no native ligands that stimulate endocytosis through a given receptor. Here we describe computational design approaches for endocytosis-triggering binding proteins (EndoTags) that overcome these challenges. We present EndoTags for insulin-like growth factor 2 receptor (IGF2R) and asialoglycoprotein receptor (ASGPR), sortilin and transferrin receptors, and show that fusing these tags to soluble or transmembrane target protein binders leads to lysosomal trafficking and target degradation. As these receptors have different tissue distributions, the different EndoTags could enable targeting of degradation to different tissues. EndoTag fusion to a PD-L1 antibody considerably increases efficacy in a mouse tumour model compared to antibody alone. The modularity and genetic encodability of EndoTags enables AND gate control for higher-specificity targeted degradation, and the localized secretion of degraders from engineered cells. By promoting endocytosis, EndoTag fusion increases signalling through an engineered ligand-receptor system by nearly 100-fold. EndoTags have considerable therapeutic potential as targeted degradation inducers, signalling activators for endocytosis-dependent pathways, and cellular uptake inducers for targeted antibody-drug and antibody-RNA conjugates.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-024-07948-2

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 34

  1. Ahn, G. et al. LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation. Nat. Chem. Biol. 17, 937–946 (2021). · DOI · Paper page
  2. Sorkin, A. & von Zastrow, M. Endocytosis and signalling: intertwining molecular networks. Nat. Rev. Mol. Cell Biol. 10, 609–622 (2009). · DOI · Paper page
  3. Gao, H., Shi, W. & Freund, L. B. Mechanics of receptor-mediated endocytosis. Proc. Natl Acad. Sci. USA 102, 9469–9474 (2005). · DOI · Paper page
  4. Kaksonen, M. & Roux, A. Mechanisms of clathrin-mediated endocytosis. Nat. Rev. Mol. Cell Biol. 19, 313–326 (2018). · DOI · Paper page
  5. Harris, L. K. & Westwood, M. Biology and significance of signalling pathways activated by IGF-II. Growth Factors 30, 1–12 (2012). · DOI
  6. Ahn, G. et al. Elucidating the cellular determinants of targeted membrane protein degradation by lysosome-targeting chimeras. Science 382, eadf6249 (2023). · DOI · Paper page
  7. Nykjaer, A. & Willnow, T. E. Sortilin: a receptor to regulate neuronal viability and function. Trends Neurosci. 35, 261–270 (2012). · DOI · Paper page
  8. Gammella, E., Buratti, P., Cairo, G. & Recalcati, S. The transferrin receptor: the cellular iron gate. Metallomics 9, 1367–1375 (2017). · DOI · Paper page
  9. Gustafsen, C. et al. Sortilin and SorLA display distinct roles in processing and trafficking of amyloid precursor protein. J. Neurosci. 33, 64–71 (2013). · DOI · Paper page
  10. Leloup, N. et al. Low pH-induced conformational change and dimerization of sortilin triggers endocytosed ligand release. Nat. Commun. 8, 1708 (2017). · DOI · Paper page
  11. Gatter, K. C., Brown, G., Trowbridge, I. S., Woolston, R. E. & Mason, D. Y. Transferrin receptors in human tissues: their distribution and possible clinical relevance. J. Clin. Pathol. 36, 539–545 (1983). · DOI · Paper page
  12. Sahtoe, D. D. et al. Transferrin receptor targeting by de novo sheet extension. Proc. Natl Acad. Sci. USA 118, e2021569118 (2021). · DOI · Paper page
  13. Sahtoe, D. D. et al. Reconfigurable asymmetric protein assemblies through implicit negative design. Science 375, eabj7662 (2022). · DOI · Paper page
  14. Wang, R., Qi, X., Schmiege, P., Coutavas, E. & Li, X. Marked structural rearrangement of mannose 6-phosphate/IGF2 receptor at different pH environments. Sci. Adv. 6, eaaz1466 (2020). · DOI
  15. Rennick, J. J., Johnston, A. P. R. & Parton, R. G. Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics. Nat. Nanotechnol. 16, 266–276 (2021). · DOI · Paper page
  16. Cullen, P. J. & Steinberg, F. To degrade or not to degrade: mechanisms and significance of endocytic recycling. Nat. Rev. Mol. Cell Biol. 19, 679–696 (2018). · DOI · Paper page
  17. Zhang, H. et al. Covalently engineered nanobody chimeras for targeted membrane protein degradation. J. Am. Chem. Soc. 143, 16377–16382 (2021). · DOI · Paper page
  18. Paunovska, K., Loughrey, D. & Dahlman, J. E. Drug delivery systems for RNA therapeutics. Nat. Rev. Genet. 23, 265–280 (2022). · DOI · Paper page
  19. Brown, J., Jones, E. Y. & Forbes, B. E. Keeping IGF-II under control: Lessons from the IGF-II–IGF2R crystal structure. Trends Biochem. Sci 34, 612–619 (2009). · DOI
  20. Steiner, P. et al. Tumor growth inhibition with cetuximab and chemotherapy in non–small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor. Clin. Cancer Res. 13, 1540–1551 (2007). · DOI · Paper page
  21. Ryu, R. & Ward, K. E. Atezolizumab for the first-line treatment of non-small cell lung cancer (NSCLC): current status and future prospects. Front. Oncol. 8, 277 (2018). · DOI
  22. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012). · DOI · Paper page
  23. Walker, L. S. K. & Sansom, D. M. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat. Rev. Immunol. 11, 852–863 (2011). · DOI · Paper page
  24. Yang, W. et al. Design of high affinity binders to convex protein target sites. Preprint at bioRxiv https://doi.org/10.1101/2024.05.01.592114 (2024). · DOI
  25. Piraner, D. I. et al. Engineered receptors for soluble cell-to-cell communication. Preprint at bioRxiv https://doi.org/10.1101/2024.09.17.613377 (2024). · doi:10.1101/2024.09.17.613377
  26. Elkon, K. & Casali, P. Nature and functions of autoantibodies. Nat. Clin. Pract. Rheumatol. 4, 491–498 (2008). · DOI · Paper page
  27. Akerström, B., Brodin, T., Reis, K. & Björck, L. Protein G: a powerful tool for binding and detection of monoclonal and polyclonal antibodies. J. Immunol. 135, 2589–2592 (1985). · doi:10.4049/jimmunol.135.4.2589
  28. Lajoie, M. J. et al. Designed protein logic to target cells with precise combinations of surface antigens. Science 369, 1637–1643 (2020). · DOI · Paper page
  29. Langan, R. A. et al. De novo design of bioactive protein switches. Nature 572, 205–210 (2019). · DOI · Paper page
  30. Yeh, A. H.-W. et al. De novo design of luciferases using deep learning. Nature 614, 774–780 (2023). · DOI · Paper page
  31. Debacker, A. J., Voutila, J., Catley, M., Blakey, D. & Habib, N. Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug. Mol. Ther. 28, 1759–1771 (2020). · DOI · Paper page
  32. Quistgaard, E. M. et al. Revisiting the structure of the Vps10 domain of human sortilin and its interaction with neurotensin. Protein Sci. 23, 1291–1300 (2014). · DOI · Paper page
  33. Greisen, P. Jr et al. Computational design of N-linked glycans for high throughput epitope profiling. Protein Sci. 32, e4726 (2023). · DOI
  34. Zanghellini, A. et al. New algorithms and an in silico benchmark for computational enzyme design. Protein Sci. 15, 2785–2794 (2006). · DOI · Paper page

Cited by

See all 146

Metadata

Authors
Huang, B., Abedi, M., Ahn, G., Coventry, B., Sappington, I., Tang, C., Wang, R., Schlichthaerle, T., Zhang, J. Z., Wang, Y., Goreshnik, I., Chiu, C. W., Chazin-Gray, A., Chan, S., Gerben, S., Murray, A., Wang, S., O’Neill, J., Yi, L., Yeh, R., Misquith, A., Wolf, A., Tomasovic, L. M., Piraner, D. I., Duran Gonzalez, M. J., Bennett, N. R., Venkatesh, P., Ahlrichs, M., Dobbins, C., Yang, W., Wang, X., Sahtoe, D. D., Vafeados, D., Mout, R., Shivaei, S., Cao, L., Carter, L., Stewart, L., Spangler, J. B., Roybal, K. T., Greisen, P. J., Li, X., Bernardes, G. J. L., Bertozzi, C. R., & Baker, D.
Venue
Nature
Published
2024-09-25
Volume
638
Issue
8051
Pages
796-804
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W4402827225
Cited by
146
References
17
FWCI
16.85
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Designed endocytosis-inducing proteins degrade targets and amplify signals. https://app.cochat.ai/papers/10.1038/s41586-024-07948-2
The paper
Huang, B., Abedi, M., Ahn, G., Coventry, B., Sappington, I., Tang, C., Wang, R., Schlichthaerle, T., Zhang, J. Z., Wang, Y., Goreshnik, I., Chiu, C. W., Chazin-Gray, A., Chan, S., Gerben, S., Murray, A., Wang, S., O’Neill, J., Yi, L., . . . Baker, D. (2025). Designed endocytosis-inducing proteins degrade targets and amplify signals. Nature. https://doi.org/10.1038/s41586-024-07948-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.